Nordhealth Q2 2025 slides: 9.5% ARR growth with AI features launch

Nordhealth AS reported solid Q2 2025 results, with annual recurring revenue (ARR) growing 9.5% year-over-year to €45.8 million, driven by a 13.0% increase in its veterinary segment and expanded geographic reach. The company achieved positive adjusted cash flow of €1.7 million in H1 2025 and significantly narrowed its adjusted EBITDA minus CAPEX loss to -€2.2 million, demonstrating improving unit economics while investing in strategic initiatives, including the launch of new AI features for its Provet Cloud platform. Nordhealth maintains a strong balance sheet with €20.5 million cash and projects 12-17% organic growth for 2025, underpinned by ongoing enterprise customer rollouts and AI expansion.

Analysis

Nordhealth AS (NORDH) reported a solid Q2 2025, demonstrating continued progress towards profitability and strategic execution. Annual recurring revenue (ARR) grew 9.5% year-over-year to €45.8 million, primarily driven by the robust veterinary segment which expanded 13.0% YoY, while the therapy segment posted more modest 4.3% growth. A key development is the significant improvement in financial discipline; the company achieved a positive adjusted cash flow of €1.7 million in H1 2025, a substantial turnaround from a loss of €1.7 million in H1 2024, and narrowed its LTM adjusted EBITDA minus CAPEX loss to -€2.2 million. Strategically, the launch of three AI features for its Provet Cloud platform marks a significant product enhancement, while geographic expansion continues with 49% of ARR now originating outside the Nordics. The company's fundamentals are underpinned by strong unit economics, evidenced by a 14.3 LTV/CAC ratio, and a solid balance sheet with €20.5 million in cash and no debt. While full-year revenue growth guidance of 12-17% was maintained, the outlook is further supported by a significant, unbooked ARR pipeline of €4.5 million from the AmeriVet rollout, indicating a clear path to future growth.

Key Decisions for Investors

• Investors should monitor the execution on key growth catalysts, particularly the pace of the AmeriVet rollout and the customer adoption rate of the new AI features, which are critical for realizing the company's guided growth.
• While the turn to positive adjusted cash flow is a significant milestone, focus should remain on the trajectory towards sustained profitability, as the company still guides for a net negative adjusted EBITDA minus CAPEX of -€4 million to -€2 million for the full year.
• It is prudent to assess the performance divergence between the high-growth veterinary segment and the slower therapy segment, paying close attention to the latter's higher churn rate of 5.4% as a potential drag on overall performance.
• The strong balance sheet with no debt provides a buffer for strategic investments, but investors should consider the impact of capital allocation decisions, such as the recent share buyback, on the company's cash reserves and future growth capacity.